Contigen Bard is approvable
This article was originally published in The Gray Sheet
Executive Summary
Bard and Collagen Corp. receive FDA approvable letter March 19 for the jointly developed bovine collagen urinary stress incontinence product. Bard says the letter requests "routine" information on labeling, clinical data and postmarket surveillance studies. If approved by the agency, Contigen Bard would be the first injectable urinary stress incontinence product on the U.S. market. Under a 1987 agreement, Collagen will manufacture the product and supply it in bulk to Bard, which will package and distribute it under a worldwide, exclusive marketing license. Upon FDA approval, Bard "will conduct FDA-required physician training and then begin a full commercial launch," the company says in a March 22 release. The premarket approval application for Contigen Bard was initially submitted in March 1989 and received an approvable recommendation from FDA's gastroenterology-urology devices panel in October 1990; the PMA was subsequently amended to respond to FDA data requests in 1991 and the fall of 1992 ("The Gray Sheet" Oct. 26, p. 15).
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.